Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Page 6 of 6
Jan 8, 2026The new offering represents a significant development in AI-driven healthcare interactions, reflecting regulatory shifts as the FDA pursues a deregulatory stance on AI and digital health tools.
TCB TeamDrug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.